Laser Capture Microdissection with Genome-Wide Expression Profiling Displayed Gene Expression Signatures in Endometrioid Endometrial Cancer

Abstract

This research determined genes contributing to the pathogenesis of endometrioid endometrial cancer (EEC). Eight pairs of microdissected EEC samples matched with normal glandular epithelium were analyzed using microarray. Unsupervised analysis identified 162 transcripts (58 up- and 104 down-regulated) that were differentially expressed (p < .01, fold change ≥ 1.5) between both groups. Quantitative real-time polymerase chain reaction (qPCR) validated the genes of interest: SLC7A5, SATB1, H19, and ZAK (p < .05). Pathway analysis revealed genes involved in acid amino transport, translation, and chromatin remodeling (p < .05). Laser capture microdissection (LCM) followed by microarray enabled precise assessment of homogeneous cell population and identified putative genes for endometrial carcinogenesis.

Genomic Expression Profiles: From Molecular Signatures to Clinical Oncology Translation

“…High expression of IGF2 (somatomedin A) was reported in mixed mullerian tumor as compared to endometrioid and papillary serous tumour (81). Our local data showed low expression of IGF2 in endometrioid endometrial cancer compared with normal endometrium (82). Low expression of IGF2 was corresponds to an early stage of endometrial cancer (83).…”

“…However, the decision whether to use the LCM technique is still relied on the ratio of stromal cells to the surrounding cancer cells. Pathways that are closely related to endometrial cancer were identified after isolation of microdissected cancerous cells was used (82). Among the significant pathways comprise of Wnt-β catenin, insulin action, cell cycle and NOTCH and B-cell pathways (82).…”

H19 promotes endometrial cancer progression by modulating epithelial-mesenchymal transition

“…However, previously H19 has been proposed as an oncogenic lncRNA in numerous cancers (14,15), and is found to positively regulate the metastatic potential of cancer cells (16,17). In endometrioid endometrial cancer tissues (18)(19)(20), overexpression of H19 exists and is associated with neoplastic cell invasion. However, the precise function of H19 in cellular processes involved in progression of endometrioid endometrial cancer is not yet understood.…”

High expression of special AT‑rich sequence binding protein‑1 predicts esophageal squamous cell carcinoma relapse and poor prognosis

“…SATB1 can regulate gene expression by folding chromatin into loop domains and tethering DNA domains to the SATB1 network structure (7,8). Under normal conditions, SATB1 is expressed at low levels in cells and tissues, but is overexpressed in a variety of malignant tumors, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular carcinoma, rectal cancer, cutaneous malignant melanoma, gastric cancer, prostate cancer, lung cancer and cutaneous T-cell lymphoma (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20).…”

“…The expression of SATB1 has been examined in esophageal adenocarcinoma and is an independent prognostic factor (20). In several types of cancer, including laryngeal squamous cell carcinoma, endometrial cancer, hepatocellular cancer and lung cancer, high expression of SATB1 promotes tumor growth and metastasis, and is a negative prognostic factor (7,(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). SATB1 can regulate the expression of >1,000 genes involved in the processes of DNA organization, proliferation and apoptosis (8,9).…”